Phanes Therapeutics' PT217 receives orphan drug designation for neuroendocrine carcinoma from the FDA
- Phanes Therapeutics' PT217 has been granted orphan drug designation (ODD) by the FDA for the treatment of neuroendocrine carcinoma (NEC).
- PT217 is a bispecific antibody targeting DLL3 and CD47, developed for NEC, a highly aggressive subgroup of neuroendocrine neoplasms.
- The ODD provides benefits such as financial incentives and up to seven years of market exclusivity in the U.S. upon regulatory approval.
- Phanes is also conducting three Phase I clinical trials, including the MORNINGSTAR, TWINPEAK, and SKYBRIDGE studies.
Read more
MMRF announces new publication on CoMMpass study in Nature Genetics
- The CoMMpass study is the largest single sequencing study of multiple myeloma patients to date.
- Findings define distinct subtypes and identify high-risk genetic markers of multiple myeloma.
- The study enrolled 1,143 patients across 76 clinical sites in four countries, followed for at least eight years.
- Data show that advanced molecular diagnostics are better predictors of disease behavior than current staging systems.
Read more
